Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
We conducted a prospective, multicenter, open-label randomized trial to compare the
antifungal effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF),
Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) or a combination of rhGM-CSF and
rhG-CSF for neutropenic patients undergoing allogeneic stem cell transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
Xiamen Amoytop Biotech Co., Ltd.
Collaborator:
Shanghai Jiao Tong University Affiliated First People's Hospital